Atreca, Inc. (BCEL)

0.0820 +0.0020 (+2.45%) As of 09:39AM EDT. Market open.

Atreca, Inc.

835 Industrial Road
Suite 400
South San Francisco, CA 94070
United States
650 595 2595
https://www.atreca.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 90

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John A. Orwin M.B.A.	President, CEO, Director & Principal Financial Officer	927.03k	N/A	1965
Dr. Tito A. Serafini Ph.D.	Founder & Director	665.5k	N/A	1963
Mr. Rick Ruiz	Principal Accounting Officer	N/A	N/A	1964
Ms. Courtney J. Phillips J.D.	General Counsel & Corporate Secretary	N/A	N/A	1975
Roger Richard Ruiz	Vice President of Finance	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Corporate governance

Atreca, Inc.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.